At our hospital we routinely use many of these therapies even in patients with a variety of autoimmune conditions. In about a third of patients, they'll have an

At our hospital we routinely use many of these therapies even in patients with a variety of autoimmune conditions. In about a third of patients, they'll have an exacerbation of their underlying autoimmune condition, which fortunately only rarely necessitates cessation of the immunotherapy. One of several studies we reference when we treat these patients: https://www.ncbi.nlm.nih.gov/pubmed?term=27687304 https://www.ncbi.nlm.nih.gov/pubmed?term=27687304 What's interesting (and increasingly being studied) is the higher risk of developing an autoimmune condition after treatment with some of these immunotherapies. The absolute risk doesn't seem to be huge, but it's an interesting window into how these conditions might develop in the first place.